PIVKA-II: A biomarker for diagnosing and monitoring patients with pancreatic adenocarcinoma.

Sara TartaglionePatrizia ManciniValentina ViggianiPiero ChirlettiAntonio AngeloniEmanuela Anastasi

Published in: PloS one (2021)

These data are the first showing a decreased PIVKA-II serum levels after surgery in PDAC patients and reporting PIVKA-II expression in PDAC tissue. Further studies are needed to confirm these findings and to determine PIVKA-II usefulness in diagnosing and monitoring PDAC patients.

Keyphrases

end stage renal disease
ejection fraction
newly diagnosed
chronic kidney disease
peritoneal dialysis
prognostic factors
poor prognosis
emergency department
electronic health record
patient reported outcomes
deep learning
binding protein
case control